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Abstract: Background: The marine-derived triterpenoid frondoside A inhibits the
phosphatidylinositol-3-kinase (PI3K) pathway in cancer cells. Because this pathway is also crucially
involved in platelet activation, we studied the effect of frondoside A on thrombus formation. Methods:
Frondoside A effects on platelet viability, surface adhesion molecule expression, and intracellular
signaling were analyzed by flow cytometry and Western blot. The effect of frondoside A was analyzed
by photochemically induced thrombus formation in the mouse dorsal skinfold chamber model
and by tail vein bleeding. Results: Concentrations of up to 15 µM frondoside A did not affect the
viability of platelets, but reduced their surface expression of P-selectin (CD62P) and the activation of
glycoprotein (GP)IIb/IIIa after agonist stimulation. Additional mechanistic analyses revealed that
this was mediated by downregulation of PI3K-dependent Akt and extracellular-stimuli-responsive
kinase (ERK) phosphorylation. Frondoside A significantly prolonged the complete vessel occlusion
time in the mouse dorsal skinfold chamber model of photochemically induced thrombus formation
and also the tail vein bleeding time when compared to vehicle-treated controls. Conclusion: Our
findings demonstrated that frondoside A inhibits agonist-induced CD62P expression and activation of
GPIIb/IIIa. Moreover, frondoside A suppresses thrombus formation. Therefore, this marine-derived
triterpenoid may serve as a lead compound for the development of novel antithrombotic drugs.
Keywords: frondoside A; thrombus formation; thrombosis; hemostasis; platelets; PI3K; dorsal
skinfold chamber
1. Introduction
Thrombus formation is triggered by intravascular blood clotting as a result of hyperaggregability
of platelets, increased blood viscosity, and impaired fibrinolysis. Antithrombotic compounds can be
divided into two classes, anticoagulants and antiplatelet drugs [1]. Antiplatelet drugs target specific
surface proteins, including adenosine diphosphate (ADP) and glycoprotein (GP)IIb/IIIa receptors,
as well as intracellular proteins, such as cyclooxygenase [2]. These drugs bear an increased risk of
bleeding and antiplatelet drug resistance. Therefore, the identification of novel compounds with
improved efficacy and safety is of major interest for the treatment of thrombotic diseases.
Platelet activation is induced by various phospho-regulated pathways, including
phosphatidylinositol-3-kinase (PI3K) [3]. All PI3K isoforms are expressed in platelets, and agonist-
induced platelet stimulation leads to the generation of phosphatidylinositol 3,4,5-trisphosphate
(PIP3) [4]. This, in turn, results in Akt and extracellular-stimuli-responsive kinase (ERK)1/2
phosphorylation as well as subsequent platelet activation [4–6]. Activated platelets express specific
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proteins, such as GPIIb/IIIa and P-selectin on their surface, which mediate platelet aggregation and
hemostatic plug formation [7–10].
Frondoside A, a triterpenoid, was originally isolated from an extract of the Atlantic sea cucumber
Cucumaria frondosa, and cannot chemically be synthesized due to its complex structure [11,12]
(Figure 1A). Several studies have reported that frondoside A exerts an antiproliferative and
pro-apoptotic activity [13–16]. Moreover, this compound is capable of potentiating the anticancer effects
of conventional cytotoxic drugs such as gemcitabine and 5-fluorouracil [13,16]. Detailed molecular
analyses revealed that these effects are mainly mediated by the inhibition of PI3K, resulting in reduced
Akt signaling and caspase-induced cell death [17–19].
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Figure 1. Effect of frondoside A on platelet viability. (A) Molecule structure of frondoside A. (B) 
Platelet-rich plasma (PRP) was incubated with different concentrations of frondoside A (black bars, n 
= 5) or vehicle (white bar, n = 5) for 30 min. Untreated PRP served as negative control (grey bar, n = 
5). H2O2-treated PRP served as positive control (shaded gray bar, n = 5). Platelet viability was assessed 
by flow cytometry. Data are given in % of vehicle. Mean ± SD. * p < 0.05 vs. vehicle. (C) Platelet-poor 
plasma (PPP) was incubated with different concentrations of frondoside A (black bars, n = 5) or vehicle 
(white bar, n = 5) for 30 min and pTT was assessed by the determination of clotting time. Untreated 
PPP (gray bar, n = 5) and normal plasma (shaded gray bar, n = 5) served as negative controls. 
Abnormal plasma (dotted gray bar, n = 5) served as positive control. Mean ± SD. * p < 0.05 vs. vehicle. 
(D) PRP was incubated with frondoside A (15 µM) or vehicle for 30 min, and the expression of the 
PI3K subunit p110δ and α-tubulin was analyzed by Western blot. (E) Quantitative analysis of the PI3K 
subunit p110δ expression (black bar, frondoside A; white bar, vehicle; n = 3). Data are given in % of 
vehicle. Mean ± SD. 
Figure 1. Effect of frondoside A latelet viability. (A) Molecule structu e of frondoside A.
(B) Platelet-rich plas a (PRP) was incubated with different concentrations of frondoside A (black
bars, n = 5) or vehicle (white bar, n = 5) for 30 min. Untreated PRP served as negative control (grey
bar, n = 5). H2O2-treated PRP served as positive control (shaded gray bar, n = 5). Platelet viability
was assessed by flow cytometry. Data are given in % of vehicle. Mean ± SD. * p < 0.05 vs. vehicle.
(C) Platelet-poor plasma (PPP) was incubated with different concentrations of frondoside A (black bars,
n = 5) or vehicle (white bar, n = 5) for 30 min and pTT was assessed by the determination of clotting
time. Untreated PPP (gray bar, n = 5) and normal plasma (shaded gray bar, n = 5) served as negative
controls. Abnormal plasma (dotted gray bar, n = 5) served as positive control. Mean ± SD. * p < 0.05 vs.
vehicle. (D) PRP was incubated with frondosid A (15 µM) or vehicle for 30 min, and the expression of
the PI3K subunit p110δ and α-tubulin was analyzed by Western blot. (E) Quantit tive a alysis of the
PI3K subunit p110δ expression (black bar, frondoside A; white bar, vehicle; n = 3). Data are given in %
of vehicle. Mean ± SD.
Based on the inhibitory properties of frondoside A on PI3K signaling, we assumed that this
compound exerts an antithrombotic activity. To test this hypothesis, we first investigated the effects of
frondoside A on platelet viability, activated partial thromboplastin time (pTT), and platelet activation.
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Furthermore, we analyzed the antithrombotic effect of frondoside A in vivo on photochemically
induced thrombus formation in the mouse dorsal skinfold chamber model and on prolongation of tail
vein bleeding time.
2. Results
2.1. Effect of Frondoside A on Platelet Viability
In a first set of experiments, we determined suitable concentrations of frondoside A to exclude
the possibility that the analyzed effects of this compound may be due to platelet toxicity. For this
purpose, platelet-rich plasma (PRP) was incubated with different concentrations of frondoside A
ranging from 5 µM to 60 µM and the viability of calcein-acetomethoxy (AM)/CD42b-stained platelets
was analyzed by means of flow cytometry. These analyses demonstrated that concentrations up to
15 µM did not exert any toxic effect on platelets (Figure 1B). In contrast, 30 µM slightly and 60 µM
significantly reduced platelet viability. Accordingly, we used concentrations of 5–15 µM frondoside A
for the following experiments.
Next, we investigated whether non-toxic concentrations of frondoside A affected the intrinsic
coagulation cascade by assessing the pTT. Normal and abnormal plasma served as positive and
negative controls, respectively, in this experimental setting. We found that the compound did not
prolong the pTT when compared to vehicle (Figure 1C).
PI3K is a major regulator of platelet activation. To exclude the possibility that frondoside A
affects the expression of this kinase, we performed additional Western blot analyses. These analyses
demonstrated that a concentration of 15 µM frondoside A did not attenuate the expression of PI3K,
as shown by a comparable level of the PI3K subunit p110δ in frondoside-A- and vehicle-treated PRP
(Figure 1D,E).
2.2. Effect of Frondoside A on Platelet Activation
Platelet aggregation is mediated by specific surface adhesion molecules. To analyze the effect of
frondoside A on this process, the expression and activation of the two adhesion proteins P-selectin
(CD62P) and GPIIb/IIIa were analyzed by flow cytometry. For this purpose, PRP was incubated
with different concentrations of frondoside A for 30 min, followed by agonist stimulation with
protease-activated receptor-1-activating peptide (PAR-1-AP), ADP, and phorbol-12-myristate-13-acetate
(PMA). As expected, the three agonists markedly increased the surface expression of P-selectin
(Figure 2A,C,E) and the activity of GPIIb/IIIa (Figure 2B,D,F). It was of note that frondoside A
concentration-dependently decreased the expression of P-selectin and suppressed the conformal switch
of inactive GPIIb/IIIa into its active form (Figure 2A–F).
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Figure 2. Effect of frondoside A on platelet activati . (A–F) PRP was incubated with different
concentrations of frondoside A (black bars, n = 5) or vehicle ( hite bars, n = 5) for 30 min following
stimulation with PAR-1-AP (A,B), ADP (C,D), or PMA (E,F) for 10 min. Surface levels of activated
GPIIb/IIIa and CD62P were assessed by means of flow cytometry. Unstimulated PRP served as negative
control (gray bars, n = 5). Data are given in % of vehicle. Mean ± SD. * p < 0.05 vs. vehicle.
2.3. Effect of Frondoside A on PI3K Signaling
Previous studies have demonstrated that frondoside A is capable of inhibiting the PI3K pathway,
which is known to be crucial for platelet activation. Therefore, we further investigated the influence of
this compound on the activity of the PI3K downstream effectors Akt and ERK1/2. Western blot analyses
revealed that agonist-induced platelet activation increased the phosphorylation of Akt and ERK1/2,
which, in turn, was suppressed by frondoside A (Figure 3A–I). These findings clearly indicated that
frondoside A inhibits platelet activation by interfering with the PI3K pathway.
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2.4. Effect of Frondoside A on Thrombus Formation In Vivo  
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mice were treated with frondoside A and vehicle as well as clopidogrel, which was chosen as a 
Figure 3. Effect of frondoside A on PI3K signaling. (A–I) PRP was incubated with frondoside A
(15 µM) or vehicle for 30 min followed by stimulation with PAR-1-AP (A), ADP (D), or PMA (G) for
10 min. Untreated PRP served as negative control. The expressions of pAkt, Akt, pERK1/2, ERK1/2,
and α-tubulin were analyzed by means of Western blot. Quantitative analysis of pAkt/Akt expression
(B,E,H) and pERK/ERK expression (C,F,I) (black bars, frondoside A; white bars, vehicle; gray bars,
untreated control; n = 3) of (A), (D) and (G), respectively. Data are given in % of vehicle. Mean ± SD.
* p < 0.05 vs. vehicle.
2.4. Effect of Frondoside A on Thrombus Formation In Vivo
Finally, we tested the antithrombotic activity of frondoside A on photochemically induced
thrombus formation in the dorsal skinfold chamber model (Figure 4A,B). For this purpose, BALB/c
mice were treated with frondoside A and vehicle as well as clopidogrel, which was chosen as a
positive control due to its well-known antithrombotic activity [20]. Subsequently, the complete vessel
occlusion time of postcapillary and collecting venules was measured. To exclude the possibility
that this measurement was affected by altered microcirculatory conditions, we first analyzed the
diameters and centerline red blood cell (RBC) velocities of these vessels. This analysis did not show any
differences between the three groups (Figure 4C,D). In line with our in vitro results, we further found
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that frondoside A significantly prolonged the vessel occlusion time (Figure 4E). Moreover, frondoside
A also significantly prolonged the tail vein bleeding time when compared to vehicle-treated controls
(Figure 4F).
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Figure 4. Effect of frondoside A on thrombus formation in vivo. (A,B) Intravital fluorescent microscopic
images of a postcapillary venule within the dorsal skinfold chamber of a vehicle-treated mouse before
(baseline) and after photochemically induced thrombus formation (asterisk). Blue-light epi-illumination
with contrast enhancement by 5% FITC-labeled dextran 150,000 Da. Scale bar: 50 µm. (C,D) Diameter
(C) and centerline RBC velocity (D) of postcapillary and collecting venules within the dorsal skinfold
chamber of mice treated with frondoside A (black bars, n = 6), vehicle (white bars, n = 6) and clopidogrel
(shaded gray bar, n = 6). Mean ± SD. (E) Complete occlusion time of postcapillary and collecting
venules upon photochemically induced thrombus formation in dorsal skinfold chambers of mice
treated with frondoside A (black bar, n = 6), vehicle (white bar, n = 6) and clopidogrel (shaded gray bar,
n = 6), as assessed by intravital fluorescence microscopy. Mean ± SD. * p < 0.05 vs. vehicle. (D) Tail
vein bleeding time of mice treated with frondoside A (black bar, n = 6), vehicle (white bar, n = 6) and
clopidogrel (shaded gray bar, n = 6). Mean ± SD. * p < 0.05 vs. vehicle. # p < 0.05 vs. frondoside A.
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3. Discussion
Marine-derived compounds provide many of the lead structures used as templates for the
generation of novel molecules with enhanced biological activity. Several of these compounds are
already being used for the treatment of different pathological conditions, including cancer, viral and
fungal infections, inflammatory diseases, and thrombosis [21]. The latter is mainly controlled by
phospho-regulated signaling transductions, such as the PI3K pathway. In this study, we identified the
triterpenoid frondoside A from the Atlantic sea cucumber Cucumaria frondosa as a novel antithrombotic
compound which is capable of reducing agonist-induced platelet activation via the inhibition of
this pathway.
We first determined suitable non-toxic concentrations of frondoside A. We found that
concentrations of 5–15 µM frondoside A did not affect the viability of platelets. In contrast, Dyshlovoy
et al. demonstrated that treatment of the human prostate cancer cell lines DU145 and PC3 with much
lower concentrations of only 1–2 µM frondoside A already induced caspase3/7 and PARP cleavage,
resulting in a reduced cell viability [14]. These contradictory findings may be explained by a different
sensibility of the cell types used. Moreover, the binding to soluble proteins within PRP, such as human
serum albumin (HSA) or immunoglobulins, may have interfered with the uptake of frondoside A
into platelets [22]. Therefore, higher concentrations of the compound were needed to exert detectable
antithrombotic effects in our experimental setting.
Primary hemostasis is triggered by various signaling pathways within platelets. Several studies
have shown that the class I PI3Ks (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ) are the most important mediators
in these cells, leading to platelet activation, spreading, and aggregation [3]. Although we found that
frondoside A does not affect the expression of PI3K, it markedly reduced the activity of the PI3K
pathway, as shown by a diminished agonist-induced phosphorylation of Akt and ERK1/2. This was in
line with the results of Park et al. showing that frondoside A significantly inhibited PI3K/Akt, ERK1/2,
and p38 MAPK activation in PMA-stimulated breast cancer cells [18].
Under hemostatic conditions, platelets do not bind to other cell types or to soluble plasma proteins.
However, when activated, they strongly interact with leukocytes, von Willebrand factor (vWF),
and fibrinogen via specific surface adhesion molecules [23]. Accordingly, we investigated the inhibitory
effect of frondoside A on the expression of two major platelet adhesion molecules. Flow cytometric
analyses revealed that 5–15 µM of the compound reduced the agonist-induced expression of P-selectin
and prevented the shift of GPIIb/IIIa from a low- to a high-affinity state following PAR-1-AP stimulation.
This concentration-dependent reduction was not observed between a frondoside A concentration of 10
and 15 µM following ADP and PMA stimulation. These contradictory findings may be explained by
the fact that PAR-1-AP only activates the Gq-coupled receptor [24]. Gq, in turn, activates phospholipase
(PLC)-β, leading to platelet shape change, granule secretion, and amplification of platelet activation [25].
In contrast, ADP activates platelets through both the Gq- and Gi-coupled receptor, whereas PMA solely
activates the Gi-coupled receptor [26,27]. The latter induces the activation of GPIIb/IIIa and stabilizes
platelet aggregation [25]. Our results indicated that 10 µM frondoside A seems to be sufficient to
completely suppress Gi signal transduction, while a higher concentration of 15 µM is necessary to
efficiently inhibit the Gq-coupled receptor. It should be considered that frondoside A may also affect
the expression of other adhesion molecules, such as GPIb/V/IX. This receptor mediates the adhesion of
platelets to exposed extracellular matrix (ECM) compounds from the disrupted endothelial lining [28].
Other interesting candidates may be the integrins α2β1 and αVβ3, which induce platelet activation
and aggregation by interaction with collagen and RGD-containing proteins [28].
For our in vitro experiments, we used the agonists PAR-1-AP and ADP for PI3K-mediated platelet
activation. In addition, platelets were stimulated with PMA, which is a strong protein kinase (PK)C
agonist [29]. It was of note that frondoside A decreased platelet activation induced by all three agonists.
Hence, our findings indicate that PKC may also be an important target of frondoside A. Besides a
direct inhibition of this kinase, frondoside A may alternatively affect signaling pathways involved in
the regulation of PKC expression and activation.
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Finally, we assessed the antithrombotic effect of frondoside A in a well-established in vivo model.
For this purpose, thrombus formation was induced in postcapillary and collecting venules within
mouse dorsal skinfold chambers by administration of the fluorescent dye fluorescein isothiocyanate
(FITC)-labeled dextran 150,000 and blue light exposure. This leads to the disruption of the endothelial
lining by local generation of reactive oxygen species [30,31]. As expected, we measured a prolonged
complete vessel occlusion time in animals treated with frondoside A when compared to vehicle-treated
controls. Moreover, similar to the positive control used herein, clopidogrel [20,32–34], the compound
increased the tail vein bleeding time.
The PI3K pathway has been shown to be a dominant signaling pathway in different nucleate
cell types, which regulates the balance between apoptosis and survival [34]. Several groups have
reported that frondoside A exerts potent anti-cancer effects in vitro and in vivo [19,35]. It is conceivable
that this compound also affects the viability of non-malignant cells, such as platelets. However,
Marzouqi et al. [36] showed that the treatment of mice with frondoside A over 24 days did not influence
the number of white blood cells, red blood cells, or platelets. Based on this finding, we assumed that
the prolonged blood vessel occlusion time observed herein was caused by a suppressed platelet activity
rather than a reduced platelet viability.
The suppression of platelet activation by frondoside A may be mediated by different mechanisms.
In addition to its well-studied inhibitory effect on the ATP-stimulated phosphorylation of several
kinase pathways, including PI3K [17], frondoside A has been shown to block the activity of
the multidrug-resistant P-glycoprotein by direct interaction [37]. Platelets also express different
glycoproteins on their surface. Hence, frondoside A may suppress platelet function by binding to
these surface proteins. On the other hand, the steroidal backbone of the molecule may also affect
platelet activity. In line with this assumption, it has been reported that estrogen decreases inositol
1,4,5-triphosphate (IP3) and increases cAMP levels in ADP-treated platelets, resulting in reduced
platelet activation [38]. Moreover, progesterone and estradiol suppress agonist-induced platelet
aggregation [39]. The modification of specific chemical groups of frondoside A could improve the
antithrombotic activity. However, it is not possible to synthesize this molecule due to its complex
structure. Therefore, further studies are required not only to clarify the exact mode of action of
frondoside A, but also to develop synthesis methods for frondoside A.
In summary, our findings demonstrated that frondoside A is a potent inhibitor of the PI3K pathway
in platelets and, thus, suppresses thrombus formation. Hence, this marine-derived triterpenoid may
serve as a lead compound for the development of novel antithrombotic drugs.
4. Materials and Methods
4.1. Chemicals, Reagents, and Antibodies
Frondoside A, ADP, PAR-1-AP, PMA, FITC-labeled dextran 150,000, and rhodamine 6G were
purchased from Sigma-Aldrich (Taufkirchen, Germany), calcein-AM from Molecular Probes (Eugene,
OR, USA), clopidogrel from Sanofi (Frankfurt, Germany), ketamine (Ursotamin®) from Serumwerke
Bernburg (Bernburg, Germany), and xylazine (Rompun®) from Bayer (Leverkusen, Germany).
Anti-CD42b, anti-CD62P, anti-GPIIb/IIIa, and IgG1-κ isotype controls were purchased from BD
Biosciences (Heidelberg, Germany). The antibodies against α-tubulin (sc-53646) and phospho
(p)-Akt1/2/3 (sc-33437) were obtained from Santa Cruz Inc. (Heidelberg, Germany). The antibodies
against p-ERK (50011) and anti-ERK (115799) were purchased from Abcam (Cambridge, UK).
The antibody against anti-Akt1/2/3 (11E7) was purchased from Cell Signaling (Frankfurt am Main,
Germany).
4.2. Ethics Statement
For the isolation of PRP, venous blood was drawn from six healthy volunteers after obtaining
their written informed consent and with the approval of the local ethics review board.
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4.3. Preparation of PRP and Platelet Poor Plasma (PPP)
In order to prepare PRP, venous blood was drawn into plastic syringes containing 0.1 volume of
3.2% trisodium citrate. PRP was collected as the supernatant after centrifuging the blood at 100× g for
20 min at room temperature. For the generation of PPP, PRP was additionally centrifuged at 2200× g
for 3 min. After centrifugation, the supernatant (PPP) was collected.
4.4. Viability Tests
PRP was incubated with different concentrations of frondoside A or vehicle (aqua dest.) for 30 min.
Thereafter, 1 µL of calcein-AM (8 µM) and a saturating concentration of PE-labeled anti-CD42b antibody
were added to 40 µL PRP for 30 min. The level of double-fluorescent events was assessed by means of
a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) using the CellQuest software.
4.5. Assessment of pTT
PPP (100 µL) was preincubated with pTT reagent (HYPHEN BioMed, Neuville-sur-Oise, France)
for 3 min at 37 ◦C, and the reaction was started by adding 100 µL (25 mM) CaCl2. The pTT was
determined as the time interval between the addition of CaCl2 to the solution and the formation of a
fibrin clot under stirring conditions. Normal and abnormal plasma served as controls.
4.6. Western Blot Analysis
PRP was incubated for 30 min with different concentrations of frondoside A or vehicle (aqua dest.),
and then stimulated with ADP (10 µM), PAR-1-AP (2.5 µM), or PMA (100 ng/mL) for 5 min. The cells
were centrifuged for 3 min by 4 ◦C and lysed on ice for 10 min in lysis buffer (RIPA buffer: 50 mM
Tris-HCl, pH 7.2, 0.15 M NaCl, 1.0 mM EDTA, 0.1% SDS, 1.0% Triton X-100, 1.0% sodium deoxycholate,
and phosphatase inhibitor). Cell extracts were separated through a 10% SDS polyacrylamide gel and
immunoblotted with specific antibodies. Protein expression was visualized via luminol-enhanced
chemiluminescence (ECL; GE-Healthcare, Freiburg, Germany) and exposure of the membranes to a
blue light-sensitive autoradiography film (Hyperfilm ECL, GE-Healthcare).
4.7. Analysis of Surface Adhesion Protein Expression
PRP was treated with different concentrations of frondoside A or vehicle (aqua dest.) for 30 min
and then stimulated with ADP (10 µM), PAR-1-AP (2.5 µM) or PMA (100 ng/mL) for 5 min. Aliquots
of 10 µL PRP were then incubated with saturating concentrations of PE-labeled primary antibodies or
control antibody (isotype control) for 30 min. Subsequently, the cells were fixed in 1% formalin for
10 min at 4 ◦C and measured using a FACScan flow cytometer (Becton Dickinson) using the CellQuest
software. The levels of CD62P and GPIIb/IIIa of 100,000 cells were determined by analyzing the mean
fluorescence intensity. Non-stimulated PRP served as controls.
4.8. Animals
For the in vivo experiments, we used male and female BALB/c mice with a body weight of
22–25 g. The animals were housed in a temperature-controlled environment under a 12 h/12 h
light–dark cycle, and received standard pellet food (Altromin, Lage, Germany) and water ad libitum.
All experiments were approved by the local governmental animal protection committee (Landesamt für
Verbraucherschutz, Abteilung C Lebensmittel- und Veterinärwesen, Saarbrücken, Germany) and were
conducted in accordance with the European legislation on protection of animals (Guideline 2010/63/EU)
and the NIH guidelines for the care and use of laboratory animals (http://oacu.od.nih.gov/regs/index.htm.
8th Edition; 2011).
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4.9. Photochemically Induced Thrombus Formation
To analyze the effect of frondoside A on photochemically induced thrombus formation, we used
the mouse dorsal skinfold chamber model [40]. For this purpose, 12 BALB/c mice were anesthetized
with an intraperitoneal injection (i.p.) of 100 mg/kg ketamine and 12 mg/kg xylazine. Subsequently,
dorsal skinfold chambers were implanted, as previously described [41]. To avoid alterations of the
microcirculation due to anesthesia or surgical trauma, the mice were allowed to recover from the
implantation procedure for 72 h. Thereafter, the animals were treated with 800µg/kg i.p. (corresponding
to a concentration of ~0.6 µM in the circulation) frondoside A (n = 6), vehicle (aqua dest. i.p.; n = 6),
or 5 mg/kg i.p. clopidogrel (n = 6) both 15 h and 1 h before photochemically induced thrombus
formation. For in vivo microscopy, mice were immobilized on a Plexiglas stage and the dorsal skinfold
chamber was attached to the microscopic stage. After retrobulbary injection of 0.05 mL 5% FITC-labeled
dextran 150,000 for contrast enhancement by staining of blood plasma and rhodamine 6G for in situ
staining of platelets, intravital epi-illumination fluorescence microscopy was performed using a Zeiss
microscope (Zeiss, Oberkochen, Germany) with a 100 W mercury lamp attached to a blue filter.
The microscopic images were recorded by a charge-coupled device video camera (FK6990; Pieper,
Schwerte, Germany) and transferred to a monitor (Trinitron; Sony, Tokyo, Japan) and DVD system
(DVD-HR775; Samsung, Eschborn, Germany) for offline evaluation. Using a 20-fold long distance
objective (Achroplan 0.50 W; Zeiss), baseline blood flow was monitored in individual postcapillary and
collecting venules (diameter range: 15–25 µm; n = 4 per chamber). Subsequently, thrombus formation
was photochemically induced by a continuously applied local exposure of the vessels to filtered
light (450–490/>520 nm excitation/emission wavelength) with a 63-fold water immersion objective
(Achroplan 0.95 W; Zeiss) [41,42].
Quantitative analyses of the microscopic images were performed using the offline analysis system
CapImage (Zeintl, Heidelberg, Germany). Diameters and centerline RBC velocities were determined
in venules prior to thrombus induction. Diameters (d) were measured in µm perpendicularly to the
vessel path. Centerline RBC velocities (v, given in µm/s) were analyzed using the line shift method [43].
The kinetics of thrombus formation were assessed by measuring the time (given in s) until sustained
cessation of blood flow due to complete vessel occlusion.
4.10. Tail Vein Bleeding Time
The tail vein bleeding time was determined as a parameter of primary hemostasis, as previously
described [44]. Briefly, an incision was made over a lateral tail vein at a constant position of the tail.
Subsequently, the tail was immersed in saline solution (37 ◦C). The time from incision to complete
cessation of the blood stream was measured as bleeding time. At the end of the in vivo experiments,
the animals were sacrificed by means of cervical dislocation.
4.11. Statistical Analysis
Data were tested for normal distribution and equal variance. Differences between two groups
were analyzed by the Mann–Whitney rank sum test. Differences between multiple groups were
analyzed by ANOVA (parametric data) or ANOVA on ranks (non-parametric data) followed by the
Student–Newman–Keuls post hoc test (SigmaPlot 11.0; Jandel Corporation, San Rafael, CA, USA).
All values are expressed as mean ± standard error (SD). Statistical significance was accepted for a value
of p < 0.05.
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